Premas Biotech Announces Approval to Initiate Phase 1 Trials in South Africa, for Oravax's Oral Vaccine for COVID-19
Premas Biotech earlier developed a virus-like particle (VLP) vaccine candidate for Covid-19 through its proprietary D-CryptTM technology and is a JV partner in Oravax Medical Inc. together with Oramed Pharmaceuticals. Premas Biotech has licensing deal for viru